Anne L. Peters

Last updated

Anne L. Peters
Born
New York City, New York, U.S.
NationalityAmerican
Alma mater Wesleyan University
Pritzker School of Medicine at the University of Chicago
OccupationDiabetologist
Spouse Eric Roth
Children1

Anne Peters is a endocrinologist, diabetes expert, and professor of clinical medicine at the Keck School of Medicine of USC. She runs diabetes centers in well-served Beverly Hills and under-resourced East Los Angeles. She teaches physicians and people with diabetes around the world how to better treat the condition, through lifestyle, medications and technology.

Contents

Early life and education

Peters was born in New York City, New York, but spent much of her youth in Madison, Wisconsin. She attended Wesleyan University (B.A. in biology, 1979), [1] and earned an M.D. from the Pritzker School of Medicine in 1983. [2] She did her residency in Internal Medical at Stanford University Medical Center and Harbor–UCLA Medical Center and her fellowship in endocrinology at Cedars-Sinai Medical Center. [3] During her senior year of medical school she worked at Elim Hospital in Gazankulu, South Africa.

Career

Peters ran diabetes programs at Cedars, then at UCLA and finally moved to USC so she could spend more time working with the underserved. Currently she holds the rank of Professor of Clinical Medicine, Clinical Scholar, the highest clinical rank in the Keck School of Medicine of USC. She has written many articles, four books and has received many research grants. For the past 20 years she has worked with the Department of Health Services for Los Angeles County developing a county-wide system for diabetes care. [4] [5] [6] [7] [8]

Peters has been part of multiple guideline writing groups and has written national and international guidelines. These include guidelines for transitioning care, [9] the management of type 1 [10] and type 2 diabetes [11] [12] and use of diabetes devices. [13] [14] [15] [16] [17] She was a member of the ADA Professional Practice Committee writing the 2020, 2021 and 2022 ADA Standards of Care. [18] [19] [20] She, along with several colleagues, was the first to publish a large case series about the risk of a severe condition known as diabetic ketoacidosis in people taking a type of medication known as an SGLT-2 inhibitor. [21] [22]

Her work in East LA was featured in the PBS series Remaking American Medicine. [23] She received the American Diabetes Association "Outstanding Physician Clinician" Award in 2008, [24] the Bernardo Alberto Houssay Award from the National Minority Quality Forum in 2010 and the Endocrine Society Laureate Award for Outstanding Public Service in 2021. [3] [25] Multiple patients have noted her involvement in their lives—Don Rickles wrote of her in his book Rickles' Letters [26] and William Friedkin did so in The Friedkin Connection. [27] Larry King featured her on a segment of Larry King Live . She worked with Olympian Gary Hall Jr [28] and Indy car driver Charlie Kimball.

She is a Fellow of the American College of Physicians. [3]

#MeToo

In 1999, she was allegedly assaulted by a patient in an exam room at UCLA. She wrote an essay about the experience keeping the name of the patient anonymous. [29] His identity was revealed by a Vanity Fair reporter, identifying him as Les Moonves. [30] Moonves then admitted to trying to force his doctor to "kiss him". Peters' confidential testimony to the CBS lawyers, which was subsequently leaked to the press, [31] helped strip Moonves of his severance package.

Related Research Articles

<span class="mw-page-title-main">Diabetic ketoacidosis</span> Medical condition

Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of diabetes mellitus. Signs and symptoms may include vomiting, abdominal pain, deep gasping breathing, increased urination, weakness, confusion and occasionally loss of consciousness. A person's breath may develop a specific "fruity" smell. The onset of symptoms is usually rapid. People without a previous diagnosis of diabetes may develop DKA as the first obvious symptom.

<span class="mw-page-title-main">Beta cell</span> Type of cell found in pancreatic islets

Beta cells (β-cells) are specialized endocrine cells located within the pancreatic islets of Langerhans responsible for the production and release of insulin and amylin. Constituting ~50–70% of cells in human islets, beta cells play a vital role in maintaining blood glucose levels. Problems with beta cells can lead to disorders such as diabetes.

<span class="mw-page-title-main">Hyperglycemia</span> Too much blood sugar, usually because of diabetes

Hyperglycemia is a condition in which an excessive amount of glucose circulates in the blood plasma. This is generally a blood sugar level higher than 11.1 mmol/L (200 mg/dL), but symptoms may not start to become noticeable until even higher values such as 13.9–16.7 mmol/L (~250–300 mg/dL). A subject with a consistent fasting blood glucose range between ~5.6 and ~7 mmol/L is considered slightly hyperglycemic, and above 7 mmol/L is generally held to have diabetes. For diabetics, glucose levels that are considered to be too hyperglycemic can vary from person to person, mainly due to the person's renal threshold of glucose and overall glucose tolerance. On average, however, chronic levels above 10–12 mmol/L (180–216 mg/dL) can produce noticeable organ damage over time.

<span class="mw-page-title-main">Diabetic coma</span> Medical condition

Diabetic coma is a life-threatening but reversible form of coma found in people with diabetes mellitus.

<span class="mw-page-title-main">Type 2 diabetes</span> Type of diabetes mellitus with high blood sugar and insulin resistance

Type 2 diabetes (T2D), formerly known as adult-onset diabetes, is a form of diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, fatigue and unexplained weight loss. Symptoms may also include increased hunger, having a sensation of pins and needles, and sores (wounds) that do not heal. Often symptoms come on slowly. Long-term complications from high blood sugar include heart disease, stroke, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. The sudden onset of hyperosmolar hyperglycemic state may occur; however, ketoacidosis is uncommon.

<span class="mw-page-title-main">Type 1 diabetes</span> Form of diabetes mellitus

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is an autoimmune disease that originates when cells that make insulin are destroyed by the immune system. Insulin is a hormone required for the cells to use blood sugar for energy and it helps regulate glucose levels in the bloodstream. Before treatment this results in high blood sugar levels in the body. The common symptoms of this elevated blood sugar are frequent urination, increased thirst, increased hunger, weight loss, and other serious complications. Additional symptoms may include blurry vision, tiredness, and slow wound healing. Symptoms typically develop over a short period of time, often a matter of weeks if not months.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

Hyperosmolar hyperglycemic state (HHS), also known as hyperosmolar non-ketotic state (HONK), is a complication of diabetes mellitus in which high blood sugar results in high osmolarity without significant ketoacidosis. Symptoms include signs of dehydration, weakness, leg cramps, vision problems, and an altered level of consciousness. Onset is typically over days to weeks. Complications may include seizures, disseminated intravascular coagulopathy, mesenteric artery occlusion, or rhabdomyolysis.

A diabetic diet is a diet that is used by people with diabetes mellitus or high blood sugar to minimize symptoms and dangerous complications of long-term elevations in blood sugar.

<span class="mw-page-title-main">Dapagliflozin</span> Diabetes medication

Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.

<span class="mw-page-title-main">Prediabetes</span> Predisease state of hyperglycemia with high risk for diabetes

Prediabetes is a component of metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms but people with prediabetes often have obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes.

<span class="mw-page-title-main">Canagliflozin</span> Chemical compound

Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes. It is used together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.

Complications of diabetes are secondary diseases that are a result of elevated blood glucose levels that occur in diabetic patients. These complications can be divided into two types: acute and chronic. Acute complications are complications that develop rapidly and can be exemplified as diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), lactic acidosis (LA), and hypoglycemia. Chronic complications develop over time and are generally classified in two categories: microvascular and macrovascular. Microvascular complications include neuropathy, nephropathy, and retinopathy; while cardiovascular disease, stroke, and peripheral vascular disease are included in the macrovascular complications.

<span class="mw-page-title-main">Diabetes in dogs</span>

Diabetes mellitus is a disease in which the beta cells of the endocrine pancreas either stop producing insulin or can no longer produce it in enough quantity for the body's needs. The disease can affect humans as well as animals such as dogs.

Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type 2 diabetes. It is taken by mouth.

Ketosis-prone diabetes (KPD) is an intermediate form of diabetes that has some characteristics of type 1 and some of type 2 diabetes. Type 1 diabetes involves autoimmune destruction of pancreatic beta cells which create insulin. This occurs earlier in a person's life, leading to patients being insulin dependent, and the lack of natural insulin makes patients prone to a condition called diabetic ketoacidosis (DKA). Type 2 diabetes is different in that it is usually caused by insulin resistance in the body in older patients leading to beta cell burnout over time, and is not prone to DKA. KPD is a condition that involves DKA like type 1, but occurs later in life and can regain beta cell function like type 2 diabetes. However, it is distinct from latent autoimmune diabetes of adults (LADA), a form of type 1 sometimes referred to as type 1.5 that does not occur with DKA. There are also distinctions to be made between KPD and LADA as patients who exhibit KPD symptoms can regain beta cell function similar to type 2 diabetics whereas LADA will not exhibit this reclamation of beta cell function.

<span class="mw-page-title-main">Diabetes</span> Group of endocrine diseases characterized by high blood sugar levels

Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Untreated or poorly treated diabetes accounts for approximately 1.5 million deaths every year.

Ambulatory glucose profile (AGP) is a single-page, standardized report for interpreting a patient's daily glucose and insulin patterns. AGP provides both graphic and quantitative characterizations of daily glucose patterns. First developed by Drs. Roger Mazze and David Rodbard, with colleagues at the Albert Einstein College of Medicine in 1987, AGP was initially used for the representation of episodic self-monitored blood glucose (SMBG). The first version included a glucose median and inter-quartile ranges graphed as a 24-hour day. Dr. Mazze brought the original AGP to the International Diabetes Center (IDC) in the late 1980s. Since then, IDC has built the AGP into the internationally recognized standard for glucose pattern reporting.

<span class="mw-page-title-main">Abbas Eqbal Kitabchi</span> Iranian-American doctor

Abbas Eqbal Kitabchi was an Iranian-born American doctor, teacher, and research scientist, whose major contributions in the field of medicine related to the treatment of severe conditions arising from diabetes. He spent his professional career in Memphis, TN and his work influenced the practices of physicians around the nation and the world.

<span class="mw-page-title-main">Brian M. Frier</span>

Brian M. Frier is a Scottish physician, diabetologist, clinical scientist, and an Honorary Professor of Diabetes at the University of Edinburgh. He is best known for his many scientific contributions to the pathophysiological understanding of hypoglycemia, a common adverse effect of insulin therapy in diabetic patients whose societal impact has deserved increasing media attention worldwide. His honors include the R.D. Lawrence Lecture of the British Diabetic Association in 1986, the Banting Memorial Lecture at Diabetes UK in 2009, the Camillo Golgi Prize and lecture at the 53rd annual EASD conference in 2017, and the Michael Somogyi Award from the Hungarian Diabetes Association in 2004. Frier is a science book author and editor, and a science journal Chief editor. He is also regarded as an authority on the field of driving and diabetes. In 2023, Frier was accorded Honorary Life Membership by the European Association of Diabetes.

References

  1. ↑ Faught, Andrew (December 10, 2014). "ANNE PETERS '79 MD: DIABETES SURGE IS HER 'CALL TO ARMS'". Wesleyan University Magazine. Retrieved July 13, 2022.
  2. ↑ "Anne L. Peters, MD". Cardiometabolic Health Congress. Retrieved July 13, 2022.
  3. 1 2 3 "Keck School Faculty". Keck School of Medicine of USC.
  4. ↑ Ruelas, V; Iverson, E; Kiekel, P; Peters, A (2012). "The role of farmers' markets in two low income, urban communities". J Community Health. Vol. 37, no. 3. pp. 554–562. doi:10.1007/s10900-011-9479-y. PMID   21922162.
  5. ↑ Huckfeldt, PJ; Meeker, D; Peters, A; Guterman, JJ; Diaz, G Jr; Goldman, DP (2012). "Diabetes management for low-income patients in Los Angeles: two strategies improved disease control in the short term". Health Aff (Millwood). Vol. 31, no. 1. pp. 168–176. doi:10.1377/hlthaff.2011.0930. PMC   3883628 . PMID   22232107.
  6. ↑ Sequeira, PA; Montoya, L; Ruelas, V; Xing, D; Chen, V; Beck, R; Peters, AL (2013). "Continuous glucose monitoring pilot in low-income type 1 diabetes patients". Diabetes Technol Ther. Vol. 15, no. 10. pp. 855–858. doi:10.1089/dia.2013.0072. PMC   3781124 . PMID   23865840.
  7. ↑ Hillstrom, Katherine; Ruelas, Valerie; Peters, Anne; Gedebu-Wilson, Turusew; Iverson, Ellen (2014). "A Retrospective Analysis of the Capacity Built through a Community-Based Participatory Research Project Addressing Diabetes and Obesity in South and East Los Angeles". Health, Vol.6 No.12.
  8. ↑ Orrange, S; Ruelas, V; Peters, AL (December 7, 2021). "Specialized Technology Education for Pumps and Pens in Underserved Populations with Diabetes". Diabetes Technol Ther. Vol. 24, no. 4. pp. 268–275. doi:10.1089/dia.2021.0265. PMID   34809482.
  9. ↑ Peters, A; Laffel, L (2011). "American Diabetes Association Transitions Working Group. Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems: a position statement of the American Diabetes Association, with representation by the American College of Osteopathic Family Physicians, the American Academy of Pediatrics, the American Association of Clinical Endocrinologists, the American Osteopathic Association, the Centers for Disease Control and Prevention, Children with Diabetes, The Endocrine Society, the International Society for Pediatric and Adolescent Diabetes, Juvenile Diabetes Research Foundation International, the National Diabetes Education Program, and the Pediatric Endocrine Society (formerly Lawson Wilkins Pediatric Endocrine Society)". Diabetes Care. 34 (11): 2477–2485. doi:10.2337/dc11-1723. PMC   3198284 . PMID   22025785.
  10. ↑ Holt, RIG; DeVries, JH; et al. (2021). "The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetologia. 64 (12): 2609–2652. doi:10.1007/s00125-021-05568-3. PMC   8481000 . PMID   34590174.
  11. ↑ Inzucchi, SE; Bergenstal, RM; et al. (2012). "Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)". Diabetes Care. 35 (6): 1364–1379. doi:10.2337/dc12-0413. PMC   3357214 . PMID   22517736.
  12. ↑ Inzucchi, SE; Bergenstal, RM; et al. (2015). "Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes". Diabetes Care. 38 (1): 140–149. doi: 10.2337/dc14-2441 . PMID   25538310. S2CID   16704514.
  13. ↑ Heinemann, L; Fleming, GA; Petrie, JR; Holl, RW; Peters, AL (2015). "Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group". Diabetes Care.
  14. ↑ Peters, AL; Ahmann, AJ; et al. (2016). "Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline". J Clin Endocrinol Metab.
  15. ↑ Petrie, JR; Peters, AL; Bergenstal, RM; Holl, RW; Fleming, GA; Heinemann, L (2017). "Improving the clinical value and utility of CGM systems: issues and recommendations : A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group". Diabetologia. doi:10.1007/s00125-017-4463-4.
  16. ↑ Peters, AL; Ahmann, AJ; Hirsch, IB; Raymond, JK (October 5, 2018). "Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice Guidelines". Journals of the Endocrine Society.
  17. ↑ Fleming, GA; Petrie, JR; Bergenstal, RM; Holl, RW; Peters, AL; Heinemann, L (2020). "Diabetes Digital App Technology: Benefits, Challenges, and Recommendations. A Consensus Report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group". Diabetes Care.
  18. ↑ "Professional Practice Committee: Standards of Medical Care in Diabetes—2020". Diabetes Care. December 16, 2019.
  19. ↑ "Professional Practice Committee: Standards of Medical Care in Diabetes—2021". Diabetes Care. December 4, 2020.
  20. ↑ "Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2022". Diabetes Care. December 16, 2021.
  21. ↑ Peters, AL; Buschur, EO; Buse, JB; Cohan, P; Diner, JC; Hirsch, IB (2015). "Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition". Diabetes Care.
  22. ↑ Peters, AL; Henry, RR; Thakkar, P; Tong, C; Alba, M (2016). "Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes". Diabetes Care.
  23. ↑ "The Stealth Epidemic". Remaking American Medicine. October 5, 2006. PBS. Archived from the original on January 12, 2020. Retrieved January 10, 2022.
  24. ↑ "1975 - 2021 Outstanding Physician-Clinician Award". ADA.
  25. ↑ "2021 Laureate Award Recipients". Endocrine Society.
  26. ↑ Rickles, Don; Ritz, David (2008). Rickles' Letters. Simon & Schuster.
  27. ↑ Friedkin, William (2013). The Friedkin Connection. HarperCollins.
  28. ↑ "Cases: Diabetic´s Olympian Triumph". The New York Times. October 31, 2000.
  29. ↑ Peters, AL (2018). "A Physician's Place in the #MeToo Movement". Ann Intern Med. Vol. 168, no. 9. pp. 676–677. doi:10.7326/M18-0271.
  30. ↑ Cohan, William D. (September 9, 2018). "LES MOONVES ADMITS TO UNWANTED KISSING OF HIS DOCTOR 19 YEARS AGO". Vanity Fair.
  31. ↑ Stewart, James B. (December 4, 2018). "'Disaster for CBS Shareholders': Damning Report on Moonves Reveals Total Failure at Top". The New York Times.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.